Drug Overview: Rexulti

  • ID: 4533547
  • Report
  • 28 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous system.

In November 2011, Otsuka announced that it had signed a long-term agreement with Lundbeck for the development and commercialization of central nervous system products in both companies’ pipelines. Rexulti was one of Otsuka’s key assets in the deal. In return for $200m upfront, with a potential final deal value of $1.8bn, Lundbeck gained co-development and co-promotion rights to Rexulti and a depot formulation of Abilify. Lundbeck also offered Otsuka the same rights for up to three of its compounds after Phase IIb clinical trials.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW
Drug Overview
Product Profiles
Rexulti: Bipolar disorder
Rexulti: Schizophrenia
Rexulti: Depression

List of Figures
Figure 1: Rexulti for bipolar disorder - SWOT analysis
Figure 2: Rexulti for schizophrenia - SWOT analysis
Figure 3: Drug assessment summary of Rexulti for schizophrenia
Figure 4: Drug assessment summary of Rexulti for schizophrenia
Figure 5: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26
Figure 6: Rexulti for depression - SWOT analysis
Figure 7: Drug assessment summary for Rexulti in depression
Figure 8: Drug assessment summary for Rexulti in depression

List of Tables
Table 1: Rexulti drug profile
Table 2: Rexulti Phase III trials in bipolar mania
Table 3: Rexulti Phase IV trial in bipolar depression
Table 4: Rexulti drug profile
Table 5: Rexulti pivotal trial data in schizophrenia
Table 6: Rexulti sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 7: Rexulti drug profile
Table 8: Overview of pivotal trial data for Rexulti in depression
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll